Regeneron Pharmaceuticals (REGN) SEC Filings: History & Chart

Regeneron Pharmaceuticals, Inc. (REGN)REGNRegeneron Pharmaceuticals, Inc.

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Tarrytown, NY

15,410 employees

www.regeneron.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Leonard S. Schleifer

View full financials

Form	Filing Date	Accepted	Document
4	Jul 7, 2026	Jul 7, 2026	View filing
8-K	Jul 6, 2026	Jul 6, 2026	View filing
8-K	Jun 17, 2026	Jun 17, 2026	View filing
13F-HR	May 8, 2026	May 8, 2026	View filing
4	May 4, 2026	May 4, 2026	View filing
SC 13G	Apr 30, 2026	Apr 30, 2026	View filing
10-Q	Apr 29, 2026	Apr 29, 2026	View filing
8-K	Apr 29, 2026	Apr 29, 2026	View filing
ARS	Apr 24, 2026	Apr 24, 2026	View filing
DEFA14A	Apr 24, 2026	Apr 24, 2026	View filing
DEF 14A	Apr 24, 2026	Apr 24, 2026	View filing
8-K	Apr 8, 2026	Apr 8, 2026	View filing
4	Apr 3, 2026	Apr 3, 2026	View filing
SC 13G/A	Mar 27, 2026	Mar 27, 2026	View filing
4	Mar 3, 2026	Mar 3, 2026	View filing
4	Feb 23, 2026	Feb 23, 2026	View filing
144	Feb 19, 2026	Feb 19, 2026	View filing
4	Feb 11, 2026	Feb 11, 2026	View filing
4	Feb 11, 2026	Feb 11, 2026	View filing
144	Feb 9, 2026	Feb 9, 2026	View filing
144	Feb 9, 2026	Feb 9, 2026	View filing
13F-HR	Feb 6, 2026	Feb 6, 2026	View filing
10-K	Feb 4, 2026	Feb 4, 2026	View filing
8-K	Jan 30, 2026	Jan 30, 2026	View filing
8-K	Jan 12, 2026	Jan 12, 2026	View filing
4	Jan 8, 2026	Jan 8, 2026	View filing
144	Jan 7, 2026	Jan 7, 2026	View filing
4	Jan 6, 2026	Jan 6, 2026	View filing
4	Jan 6, 2026	Jan 6, 2026	View filing
4	Jan 6, 2026	Jan 6, 2026	View filing

SEC Filings

Recent Filings